Actively Recruiting
Real-World Treatment Patterns and Effectiveness of Targeted and Systemic Therapy in Patients With Advanced Lung Cancer Carrying MET Mutation-Positive
Led by Hunan Province Tumor Hospital · Updated on 2024-09-19
200
Participants Needed
1
Research Sites
25 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to understand treatment patterns and effectiveness in patients with advanced lung cancer who have a MET mutation. It is an observational study conducted in a way that does not interfere with patients' current medical care. Data will be collected both retrospectively from past treatments and prospectively from future treatments, with patient enrollment occurring after genetic analysis of tumor tissue and informed consent. The study observes patients receiving various first-line treatments including immunotherapy with or without anti-angiogenic therapy or chemotherapy, as well as treatments with savolitinib, glumetinib, or bozitinib. No new drugs or tissue sampling are introduced as part of the study. Information is gathered regularly every three months to track patient progress. Participants will be monitored for outcomes such as progression-free survival and overall survival over approximately 4.5 years. Additional assessments include the relationship between genetic profiling and these outcomes and overall response rate. The study collects data in an epidemiological manner to better understand real-world treatment effectiveness without altering patients' ongoing treatments.
CONDITIONS
Brief Title
A Real-World Study of Treatment Patterns and Effectiveness in MET Mutation-Positive Advanced Lung Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients must be 18 years of age or older
- Must provide fully informed consent before any study procedures
- Histologically or cytologically confirmed, unresectable stage IIIB, IIIC, or stage IV non-small cell lung cancer
- Genetic variants of tumor tissue detected by next-generation sequencing (NGS)
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to around 4.5 years
Participants who undergo routine care are observed to assess treatment patterns and effectiveness over time.
Periodic visits as part of routine care
Trial Site Locations
Total: 1 location
1
Hunan Province Tumor Hospital
Changsha, Hunan, China
Actively Recruiting
Research Team
Y
Yongchang Zhang, MD
N
Nong Yang
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here